Routes of
administration Oral | ||
Legal status US: Investigational New Drug | ||
R7 is a prodrug of 7,8-dihydroxyflavone (7,8-DHF) with significantly improved potency and pharmacokinetics (namely oral bioavailability) that is currently in preclinical development for the treatment of Alzheimer's disease. As a prodrug of 7,8-DHF, R7 is a selective agonist of TrkB, the main receptor of brain-derived neurotrophic factor (BDNF). 7,8-DHF shows robust efficacy in a variety of animal models of Alzheimer's disease as well as other conditions, making R7 a highly promising potential therapeutic agent. The chemical structure of the compound has yet to be published.
References
R7 (drug) Wikipedia(Text) CC BY-SA